Reigning in costs is a key component of healthcare reform. So it is clear why it will be essential for both providers and policy makers to identify those most at risk for driving up costs.
Reigning in costs is a key component of healthcare reform. So it is clear why it will be essential for both providers and policy makers to identify those most at risk for driving up costs.
According to a recent study published in The American Journal of Managed Care (AJMC), opioid analgesic—treated chronic pain (OAT-CP) patients who showed signs of trouble cost their health plan an estimated $12,877 a year. Precursors of trouble ranged from rapid dose escalation to doctor shopping.
“More than one-third of a sample of OAT-CP patients were identified as potentially problematic opioid users according to the study definitions applied. Healthcare service utilization and expenditures were significantly greater for this group compared with the control group,” reported the study authors.
According to an official press release on the findings:
Of the patients in the study, 39% showed signs of problematic behavior, which included doctor shopping (defined as receiving fills from 5 or more prescribers in a year) and rapid dose escalation (defined as either a 50% increase in opioid dose in the first 3 months or a 100% increase in the follow-up period). Compared with the control group, this group had:
However, proper caution and monitoring can reduce risk of opioid misuse or adverse outcomes.
“[There are] a number of tools and approaches clinicians should use to safely prescribe opioids,” the study said. “These include checking prescription drug monitoring programs, which track information on controlled substance prescriptions filled in a state, taking a careful history of substance abuse and other mental health problems, conducting routine urine drug screens in concert with pain management agreements, and making use of pain medicine consultants when problems arise.”
Read the full study here.
Around the Web
AJMC: Recognizing Certain Indicators Can Prevent Opioid Misuse and Overdose [AJMC]
Study: Pain Patients Who Show Signs of Trouble Cost Health Plan an Extra $12,877 a Year [AJMC]
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More